Atlas Trials

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

Clinical trial NCT01987908 · TERMINATED

Trial details

NCT number
NCT01987908
Sponsor
Baxalta now part of Shire
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell Disease
Start date
2013-12-03
Primary completion
2015-03-16
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.